Vivoryon Optimistic About Kidney Disease Treatment

Vivoryon Therapeutics AG (GB:0R3M) has released an update.

Vivoryon Therapeutics N.V. has emphasized the urgent need for novel treatments in kidney disease, despite recent advances, at their Kidney Disease KOL Event. Their lead asset, varoglutamstat, shows promise in targeting inflammatory and fibrotic pathways, particularly in diabetic kidney disease patients. The company is optimistic about varoglutamstat’s potential based on evidence from the VIVIAD Phase 2b study and looks forward to advancing clinical studies.

For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.